Zydus announces settlement of patent litigation in US

Zydus Wellness

Cadila Healthcare Limited and its subsidiary Zydus Pharmaceuticals (USA) Inc. (Zydus Cadila) today announced that they have reached an agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb relating to patents for REVLIMID (lenalidomide), company said the press release.

Cadila Healthcare was quoting at Rs 431.75, up Rs 0.70, or 0.16 percent on the BSE.

News Source:- Moneycontrol

For Enquiry Fill The Form

*Note:- Please provide a valid Email Id to receive OTP from bigprofitbuzz.com.

Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button